



ACIP Meningococcal Vaccines Work Group Introduction

Katherine Poehling, MD, MPH
Work Group Chair

February 23, 2023

Meningococcal Vaccines Work Group

- ACIP Members
 - Katherine Poehling (Chair)
 - Lynn Bahta
 - Jamie Loehr
- Ex Officio Members
 - Margaret Bash (FDA)
 - Mark Connelly (FDA)
 - Francisco Leyva (NIH)
- CDC Lead
 - Sam Crowe (DBD/NCIRD)
- Liaisons and Consultants
 - Amra Resic (AAFP)
 - Samir Shah (AAP)
 - Sharon McMullen (ACHA)
 - Cacky Tate (AIM)
 - Paul Cieslak (CSTE)
 - Jeff Goad (NFID)
 - Jessica Cataldi (PIDS)
 - Amy Middleman (SAHM)
 - David Stephens (Emory)
- CDC Contributors
 - LeAnne Fox (DBD/NCIRD)
 - Susan Hariri (DBD/NCIRD)
 - Lucy McNamara (DBD/NCIRD)
 - Alison Albert (DBD/NCIRD)
 - Noele Nelson (DBD/NCIRD)
 - Jonathan Duffy (DHQP/NCEZID)
 - Tanya Myers (DHQP/NCEZID)
 - Ismael Ortega-Sanchez (DVD/NCIRD)
 - Liz Velazquez (ISD/NCIRD)
 - Jessica MacNeil (ACIP Secretariat)
- GRADE/EtR
 - Doug Campos-Outcalt (Arizona)
 - Rebecca Morgan (McMaster)


October ACIP Meeting Recap

- Menveo one-vial presentation
- Introduction to the two new MenABCWY vaccines
 - Manufacturers: GSK and Pfizer
 - Policy questions
 - PICOs
 - Next steps

Work Group Schedule Updates

Task	2022							2023												2024					
	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6
Menveo Solution																									
Pfizer Pentavalent Vaccine																									
GSK Pentavalent Vaccine																									

Proposed Timeline of ACIP Presentations



Summary of Recent Work Group Activities

- GSK and Pfizer presented on their pentavalent vaccines and work group asked clarifying questions
- Work group discussed whether to reconsider adolescent immunization schedule
- Decided to postpone any reviews of the schedule until after both pentavalent vaccines have been assessed
 - Vaccine reviews will be complex and challenging
 - Need to understand epidemiology of meningococcal disease after COVID-19

Agenda for Today

- Epidemiology of Meningococcal Disease in the United States
 - Amy Rubis, CDC
- Pfizer's MenABCWY Vaccine Clinical Trials Data
 - Pfizer Representative
- Work Group Interpretation of Pfizer's MenABCWY Vaccine Clinical Trials Data
 - Sam Crowe, CDC

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

